Contrast Media Market Segmentation:
Modality Segment Analysis
The computed tomography segment is expected to account for a market share of 38.7% by the end of 2037, owing to high demand for CT scans to cater to rising prevalence of chronic diseases globally. Companies are investing in developing advanced computed tomography technologies and devices. For example, in May 2023, Philips launched Philips CT 3500, an AI-powered system of computed tomography that boosts the routine radiology and high-volume programs of screening through its high throughput capacity. The technology is effective in terms of productivity and for appropriate imaging at the first attempt due to the AI-powered workflow and image construction.
Application Segment Analysis
By 2037, the cardiovascular disorders segment is anticipated to acquire a market share of 48.2% owing high prevalence of cardiovascular disorders (CVDs) worldwide and growing focus on developing advanced contrast media for cardiovascular imaging. According to the WHO statistics, around 19.8 million people suffered from CVDs in 2022, and the number is expected to increase to around 40 million by 2050.
The ongoing advancements in contrast-enhanced imaging using agents, such as Lumason and Optison is expected to fuel the segment growth during the forecast period. In June 2025, GE HealthCare launched single-photon emission computed tomography-computed tomography (SPECT/CT), positron emission tomography-computed tomography (PET/CT), and Flyrcado (flurpiridaz F 18) injection to develop precision care for cardiovascular disorders.
End use Segment Analysis
The hospitals segment is expected to expand at a rapid CAGR during the forecast period, owing to advancements in healthcare infrastructure focused on integrating advanced contrast media in patient diagnosis. Hospitals globally are also initiating strategic partnerships to increase the availability of media agents that are approved by regulatory bodies. For example, in February 2023, a leading supplier of diagnostic imaging modalities, Bracco, announced the completion of the trial of its newly developed advanced contrast agent, VUEWAY (gadopiclenol) injection, at the Wellstar Health System. It is an eco-friendly macrocyclic GBCA that needs a minimal dose of gadolinium.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegments |
|
Modality |
|
|
Product |
|
|
Application |
|
|
Administration |
|
|
End use |
|
